Eisai has won full FDA approval for its Alzheimer’s disease drug, a regulatory decision that sets precedent for the review and potential approval of other therapies for the neurodegenerative disorder. However, while conversion of Leqembi’s accelerated approval to traditional approval was…
Source: medcitynews.com – Read more
Board-Ready Security Metrics That Actually Matter
TL;DR Board-ready security metrics translate technical capabilities into financial risk and business outcomes. Boards need visibility across three dimensions: risk exposure, incident response capability, and
